Nevisense Bests TEWL for Evaluating Skin Barrier Function
Scibase’s Nevisense’s electrical impedance spectroscopy (EIS) may be a better way to assess skin barrier function than the trans-epidermal water loss (TEWL) measurement technique, a new study shows. Specifically, EIS was less affected by daily activities than TEWL, according to research in the Annals of Dermatology. The study included healthy adults between 22 and 65 years of age and aimed to […]
Targeting TYRP1 With CAR T-cell Therapy May Help Treat Cutaneous and Rare Melanomas
A new chimeric antigen receptor (CAR) T-cell-based immunotherapy targeting TYRP1 may help treat patients with cutaneous and rare subtypes of melanoma, according to research out of the UCLA Health Jonsson Comprehensive Cancer Center. The new approach, as described in Nature Communications, uses an engineered CAR T-cell that is designed to recognize and attack cells with […]
COVID-19 Lockdowns Caused Major Delays in Melanoma Diagnoses, Costing Billions
Delays in diagnosing melanoma due to COVID-19 lockdown may have contributed to more than 100,000 years of life lost across Europe and over £6 billion mainly indirectly due to loss of productivity, according to new research in JAMA Network Open. For the study, a team of researchers from the UK, Switzerland, Germany, US, Italy, Australia and Hungary, looked at […]
Can HA-based Fillers Reverse Photoaging?
Judicious use of sunscreen remains the best way to prevent photoaging, but now new research suggests that cross-linked hyaluronic acid soft tissue fillers may reverse the dermal changes associated with photoaging. The study appears in Experimental Dermatology. Cross-linked hyaluronic acid injections can stimulates production of new type I collagen in the dermis. The filler does so […]
Breaking News: Japan First in the World to Approve Dupilumab for CSU
The Ministry of Health, Labor and Welfare (MHLW) in Japan has granted marketing and manufacturing authorization for dupilumab (Dupixent, Sanofi and Regeneron Pharmaceuticals, Inc.) for the treatment of chronic spontaneous urticaria (CSU) in people aged 12 years and older whose disease is not adequately controlled with existing therapy. Japan is the first country to approve dupilumab […]